Liver fibrosis fast facts:

25% of worldwide population

25% of worldwide population has NAFLD1

20% of the NAFLD population and 55.5% of type 2 diabetes patients have NASH disease1

NASH continues to grow

Globally, NASH prevalence is 1.5% – 6.5%2

NASH disease is expected to increase by over 50% in the next 10 years2

NASH Economic Burden

The total cost of NASH-related care in North America will amount to $593 billion between 2013 and 20333

NAFLD encompasses the spectrum of liver disease, ranging from non-alcoholic fatty liver (NAFL) to non-alcoholic steatohepatitis (NASH), fibrosis and cirrhosis

Patients at risk of NAFLD and NASH are not always identified as there are no obvious clinical manifestations and it can remain silent for several years as it progresses

Fibrosis is becoming the main predictor of NAFLD progression to NASH and if detected at an early stage it can be prevented through lifestyle changes

Currently, there is no single alternative that can provide all the information offered by a liver biopsy – consequently, there is an urgent need for non-invasive and cost-effective biomarkers to facilitate widespread surveillance

Median’s iBiopsy® NASH

Unrivalled AI/ML Software as Medical Device (SaMD) enabling liver fibrosis diagnosis with unprecedented performance

  • The only end-to-end AI/ML tech based SaMDs indicated for liver fibrosis in NASH

  • Unprecedented sensitivity and specificity performance

  • iBiopsy® has the potential to identify fibrosis when still reversible

  • Additional indications

    Lung cancer

    Lung cancer screening (LCS) & incidental pulmonary nodules (IPN)

    Liver cancer

    Very early Hepatocellular Carcinoma (HCC)

    Latest news


    Median Technologies to participate in the 2022 European Congress of Radiology (ECR), July 13 – 17, 2022, Vienna, Austria, with two presentations on iBiopsy®


    Median Technologies is moving forward with the FDA interactions for its iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device


    Median Technologies announces design completion of its iBiopsy® Lung Cancer Screening end-to-end CADe/CADx Software as Medical Device (SaMD) with outstanding sensitivity & specificity performance


    Median Technologies files FDA 513(g) regulatory submission for iBiopsy® Lung Cancer Screening CADe/CADx Software as Medical Device